<DOC>
	<DOCNO>NCT00004097</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy plus radiation therapy treat patient advanced and/or recurrent head neck cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Patients With Advanced and/or Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) gemcitabine administer paclitaxel fluorouracil concurrent hyperfractionated radiotherapy patient advance and/or recurrent head neck cancer . II . Determine MTD DLT gemcitabine single agent radiotherapy patient . III . Determine efficacy concurrent chemoradiotherapy term time progression , pattern failure , overall survival patient measurable disease . IV . Determine gemcitabine fluorouracil pharmacokinetics patient . OUTLINE : This dose escalation study gemcitabine , conduct two phase . Phase A : Patients receive fluorouracil IV continuously day 1-5 , paclitaxel IV 1 hour day 2 , radiotherapy administer twice daily day 1-5 . This regimen repeat every 2 week 2 course , gemcitabine IV 30 minute add day 2 paclitaxel . This regimen administer every 2 week 3 course . Patients responsive disease may continue chemotherapy ( without radiotherapy ) 2 course beyond maximum response . Cohorts 3-6 patient receive escalate dos gemcitabine maximum tolerate dose ( MTD ) determine . The MTD define dose 3 6 patient experience dose-limiting toxicity . Phase B : After MTD gemcitabine determine phase A , dose escalation gemcitabine may perform concurrent radiotherapy ( without fluorouracil paclitaxel ) . The MTD determine phase A . Patients follow monthly 1 year every 3 month thereafter . PROJECTED ACCRUAL : A total 30-40 patient accrue study within approximately 2 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven head neck cancer require regional radiotherapy Locoregional , recurrent disease primary therapy surgery , radiation , OR Stage IV , prior therapy , amenable conventional therapy curative intent Metastatic disease allow predominant site associate symptom require local treatment head neck region PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 2.5 time upper limit normal Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No significant infection No severe medical illness PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Recovered prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Recovered prior radiotherapy Surgery : See Disease Characteristics Recovered prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2001</verification_date>
	<keyword>stage III nasopharyngeal cancer</keyword>
	<keyword>stage IV nasopharyngeal cancer</keyword>
	<keyword>recurrent nasopharyngeal cancer</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>stage III lip oral cavity cancer</keyword>
	<keyword>stage IV lip oral cavity cancer</keyword>
	<keyword>recurrent lip oral cavity cancer</keyword>
	<keyword>stage III hypopharyngeal cancer</keyword>
	<keyword>stage IV hypopharyngeal cancer</keyword>
	<keyword>recurrent hypopharyngeal cancer</keyword>
	<keyword>stage III laryngeal cancer</keyword>
	<keyword>stage IV laryngeal cancer</keyword>
	<keyword>recurrent laryngeal cancer</keyword>
	<keyword>stage III paranasal sinus nasal cavity cancer</keyword>
	<keyword>stage IV paranasal sinus nasal cavity cancer</keyword>
	<keyword>recurrent paranasal sinus nasal cavity cancer</keyword>
	<keyword>stage III oropharyngeal cancer</keyword>
	<keyword>stage IV oropharyngeal cancer</keyword>
	<keyword>recurrent oropharyngeal cancer</keyword>
</DOC>